Silverarc Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Silverarc Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35,774	Closed	-$9.84M	–	64
2024 Q3	$9.84M	Sell	35,774 -226	-0.6%	-$58.8K	2.21%	16
2024 Q2	$8.75M	Buy	+36,000	New	+$5.68M	2.06%	14
2023 Q2	–	Sell	-14,043	Closed	-$2.81M	–	84
2023 Q1	$2.81M	Sell	14,043 -23,609	-63%	-$4.96M	1.16%	32
2022 Q4	$8.95M	Buy	37,652 +5,107	+16%	+$1.09M	2.56%	12
2022 Q3	$6.51M	Buy	+32,545	New	+$6.21M	2.2%	16

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Silverarc Capital Management's ALNY Position: Q4 2024 in Review

Silverarc Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 35,774 shares — an estimated $9.84M sold.

Silverarc Capital Management first reported a position in ALNY in Q3 2022 and held it in 5 quarters. The position peaked at $9.84M in Q3 2024. 595 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

Silverarc Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Silverarc Capital Management sold 35,774 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $9.84M.
Silverarc Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 5 quarters.
Silverarc Capital Management's Alnylam Pharmaceuticals position peaked at $9.84M in Q3 2024.
595 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.